Evaluation of 111In-labeled cyclic RGD peptides: tetrameric not tetravalent.
This report presents the synthesis and evaluation of (111)In(DOTA-6G-RGD(4)) (DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetracetic acid; 6G-RGD(4) = E{G(3)-E[G(3)-c(RGDfK)](2)}(2) and G(3) = Gly-Gly-Gly), (111)In(DOTA-RGD(4)) (RGD(4) = E{E[c(RGDfK)](2)}(2)) and (111)In(DOTA-3G-RGD(2)) (3G-RGD(2) = G(3)-E[G(3)-c(RGDfK)](2)) as new radiotracers for imaging integrin alpha(v)beta(3)-positive tumors. The IC(50) values of DOTA-6G-RGD(4), DOTA-RGD(4), and DOTA-3G-RGD(2) were determined to be 0.4 +/- 0.1, 1.4 +/- 0.1 and 1.1 +/- 0.1 nM against (125)I-c(RGDyK) bound to integrin alpha(v)beta(3)-positive U87MG human glioma cells. (111)In(DOTA-6G-RGD(4)), (111)In(DOTA-RGD(4)), and (111)In(DOTA-3G-RGD(2)) were prepared by reacting (111)InCl(3) with the respective DOTA conjugate in NH(4)OAc buffer (100 mM, pH = 5.5). Radiolabeling could be completed by heating the reaction mixture at 100 degrees C for 15-20 min. The specific activity was approximately 1850 MBq/micromol for (111)In(DOTA-3G-RGD(2)) and approximately 1480 MBq/micromol for (111)In(DOTA-6G-RGD(4)). The athymic nude mice bearing U87MG human glioma xenografts were used to evaluate tumor uptake and excretion kinetics of (111)In(DOTA-6G-RGD(4)), (111)In(DOTA-RGD(4)), and (111)In(DOTA-3G-RGD(2)). The results from both the integrin alpha(v)beta(3) binding assay and biodistribution studies suggest that the tetrameric cyclic RGD peptides, such as RGD(4) and 6G-RGD(4), are most likely bivalent in binding to the integrin alpha(v)beta(3). Both (111)In(DOTA-6G-RGD(4)) and (111)In(DOTA-RGD(4)) had significantly higher tumor uptake than (111)In(DOTA-3G-RGD(2)) at 24-72 h postinjection due to the extra RGD motifs in RGD(4) and 6G-RGD(4). (111)In(DOTA-3G-RGD(2)) had very little metabolism, while (111)In(DOTA-6G-RGD(4)) had significant metabolism during its excretion via both renal and hepatobiliary routes over the 2 h period, probably due to its much larger size. The combination of high tumor uptake with long tumor retention suggests that their corresponding (90)Y and (177)Lu analogues M(DOTA-6G-RGD(4)) (M = (90)Y and (177)Lu) might be useful as therapeutic radiotracers for treatment of integrin alpha(v)beta(3)-positive solid tumors.
Chakraborty
Sudipta
S
School of Health Sciences, Purdue University, Indiana 47907, USA.
Shi
Jiyun
J
Kim
Young-Seung
YS
Zhou
Yang
Y
Jia
Bing
B
Wang
Fan
F
Liu
Shuang
S
D000818:Animals; D045744:Cell Line, Tumor; D005910:Glioma / Q000000981:diagnostic imaging*; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry / Q000493:pharmacokinetics; D006801:Humans; D007205:Indium Radioisotopes / Q000737:chemistry* / Q000493:pharmacokinetics; D039302:Integrin alphaVbeta3 / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D009842:Oligopeptides / Q000737:chemistry* / Q000493:pharmacokinetics; D010456:Peptides, Cyclic / Q000737:chemistry / Q000493:pharmacokinetics; D011877:Radionuclide Imaging
D006573:Heterocyclic Compounds, 1-Ring; D007205:Indium Radioisotopes; D039302:Integrin alphaVbeta3; D009842:Oligopeptides; D010456:Peptides, Cyclic; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; C047981:arginyl-glycyl-aspartic acid; C035647:glycyl-glycyl-glycine
Bioconjug Chem. 2009 Aug 19;20(8):1559-68
19603780
Bioconjug Chem. 2006 Nov-Dec;17(6):1499-507
17105229
Bioconjug Chem. 2001 Jul-Aug;12(4):624-9
11459468
Chemistry. 2003 Jun 16;9(12):2717-25
12772286
Cancer Res. 2002 Nov 1;62(21):6146-51
12414640
J Nucl Med. 2008 Jun;49 Suppl 2:113S-28S
18523069
Bioconjug Chem. 2001 Jul-Aug;12(4):559-68
11459461
Bioconjug Chem. 2008 Mar;19(3):634-42
18281926
Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):267-73
16909226
Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1100-8
18204838
Mini Rev Med Chem. 2006 Feb;6(2):227-34
16472190
Mol Imaging. 2004 Apr;3(2):96-104
15296674
J Med Chem. 2008 Dec 25;51(24):7980-90
19049428
J Nucl Med. 2005 Oct;46(10):1707-18
16204722
Nucl Med Biol. 2007 Jan;34(1):29-35
17210459
J Nucl Med. 2007 Sep;48(9):1536-44
17704249
Bioconjug Chem. 2009 Dec;20(12):2199-213
19719118
J Nucl Med. 2006 Jan;47(1):113-21
16391195
Curr Pharm Des. 2004;10(13):1439-55
15134568
Mol Cancer Ther. 2006 Nov;5(11):2624-33
17121909
Mol Pharm. 2006 Sep-Oct;3(5):472-87
17009846
J Cell Biochem Suppl. 2002;39:72-8
12552605
Cancer Biother Radiopharm. 2002 Dec;17(6):641-6
12537667
Cancer Res. 1987 Jun 15;47(12):3039-51
3555767
Bioconjug Chem. 2009 Apr;20(4):750-9
19320477
Q J Nucl Med. 2001 Jun;45(2):179-82
11476168
Drugs R D. 2008;9(6):351-68
18989988
Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9
15380745
Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1874-84
19484236
Bioconjug Chem. 2006 Jul-Aug;17(4):1069-76
16848417
Curr Pharm Des. 2008;14(28):2943-73
18991712
Bioconjug Chem. 2005 Nov-Dec;16(6):1580-8
16287258
Eur J Nucl Med Mol Imaging. 2009 Aug;36(8):1296-307
19296102
Bioconjug Chem. 2008 Jan;19(1):201-10
18069778
Eur J Nucl Med Mol Imaging. 2009 Jun;36(6):947-57
19159928
Bioconjug Chem. 2007 Mar-Apr;18(2):438-46
17341108
Mol Pharm. 2009 Jan-Feb;6(1):231-45
19067525
Nucl Med Biol. 2008 Jan;35(1):111-21
18158950